Abstract
Systemic AL amyloidosis is a rare disease that is caused by the misfolding of immunoglobulin light chains (LCs). Potential drivers of amyloid formation in this disease are post-translational modifications (PTMs) and the mutational changes that are inserted into the LCs by somatic hypermutation. Here we present the cryo electron microscopy (cryo-EM) structure of an ex vivo λ1-AL amyloid fibril whose deposits disrupt the ordered cardiomyocyte structure in the heart. The fibril protein contains six mutational changes compared to the germ line and three PTMs (disulfide bond, N-glycosylation and pyroglutamylation). Our data imply that the disulfide bond, glycosylation and mutational changes contribute to determining the fibril protein fold and help to generate a fibril morphology that is able to withstand proteolytic degradation inside the body.
Introduction
Systemic AL amyloidosis occurs when plasma cells produce unstable immunoglobulin light chains (LCs). These proteins misfold into long, rigid fibers called amyloid fibrils that deposit in organs—most dangerously the heart—leading to heart failure. While somatic mutations and post-translational modifications (PTMs) are common in these patients, their influence on the final 3D structure of in vivo fibrils has remained unclear. Most previous studies relied on simplified, lab-grown versions of these proteins. This study addresses this gap by analyzing fibrils extracted directly from a patient (FOR001) to understand how the interplay of mutations and PTMs creates stable, pathogenic structures.
Methods
The researchers employed a multi-disciplinary approach to bridge the gap between clinical samples and atomic-scale physics. Fibrils were harvested from the heart tissue of a patient undergoing a heart transplant. Using a Titan Krios microscope, they achieved a 3.1 Å resolution cryo-EM reconstruction, allowing for the mapping of the polypeptide backbone and side chains. Mass spectrometry (MS) was used to identify the exact amino acid sequence and PTMs, such as glycosylation. Additionally, biophysical assays involving Thioflavin T (ThT) fluorescence and Proteinase K digestion were used to test the effects of glycosylation on aggregation speed and fibril stability.
Structural Insights and Mechanical Rigidity
The cryo-EM analysis revealed that the fibril consists of a single protofilament with a left-handed twist and a 4.76 Å rise between protein layers. Three distinct PTMs were confirmed: an intramolecular disulfide bond (Cys22–Cys89), N-glycosylation at Asn17, and N-terminal pyroglutamylation.
Beyond the atomic structure, the study examined the mechanical properties of these aggregates. Using STEM tomograms, the persistence length was calculated to be approximately 0.74 μm. This high degree of rigidity likely contributes to the mechanical disruption of heart cell membranes observed in clinical cases, as shown in the tissue imaging and persistence length plots.
The Role of Glycosylation and Mutations
A key finding is the role of N-glycosylation at position Asn17, which acts as a structural "spacer." This modification prevents the N- and C-termini of the protein from coming together, forcing the fibril into a topology distinct from non-glycosylated versions. Interestingly, in vitro experiments showed that while glycosylation slows down the formation of fibrils, the resulting structures are more stable and resistant to proteases. This suggests a "survival of the fittest" mechanism where the body’s environment selects for exceptionally persistent fibril morphologies.
Furthermore, the six mutations identified in the patient were found to cluster in regions that either destabilize the native "healthy" fold or create new stabilizing interactions, such as buried salt bridges, within the diseased fibril fold.
Conclusion and Future Directions
This study provides a high-resolution blueprint of the toxic aggregates in AL amyloidosis, highlighting glycosylation and specific mutations as active architects of fibril pathogenicity. However, as AL amyloidosis is highly patient-specific, this single structure may not represent all cases. Future research should focus on solving more ex vivo structures to determine if these topological features are universal and investigating whether specific "glycan signatures" can serve as biomarkers for disease severity or organ targeting.
Summary updated